Enhanced Guidelines for IgA Nephropathy by CSL Vifor and Travere
CSL Vifor and Travere Therapeutics Support Updated IgA Nephropathy Guidelines In a significant move for renal health, CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX), have acknowledged the recent updates to the KDIGO clinical practice guidelines for IgA nephropathy. The updated guidelines serve as an essential tool in improving the approaches to managing this...
Continue Reading